Moderna (MRNA) Declines More Than Market: Some Information for Investors

Company Performance - Moderna's stock closed at $23.51, reflecting a decline of 7.4% from the previous day, underperforming the S&P 500 which fell by 0.05% [1] - Over the past month, Moderna's shares decreased by 4.87%, lagging behind the Medical sector's gain of 7.77% and the S&P 500's increase of 3.44% [1] Upcoming Financial Results - The upcoming earnings report for Moderna is expected to show an EPS of -$1.94, representing a significant decline of 6566.67% compared to the same quarter last year [2] - Quarterly revenue is anticipated to be $962.38 million, down 48.31% from the previous year [2] Full Year Projections - For the full year, earnings are projected at -$9.7 per share and revenue at $1.92 billion, indicating changes of -9.36% and -40.61% respectively from the prior year [3] Analyst Estimates and Market Sentiment - Recent modifications to analyst estimates for Moderna reflect current business trends, with upward revisions indicating positive sentiment towards the company's operations [4] - Changes in estimates are linked to stock price performance, and investors can utilize the Zacks Rank for actionable insights [5] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that 1 stocks have an average annual return of +25% since 1988 [6] - Currently, Moderna holds a Zacks Rank of 3 (Hold), with a recent 0.5% rise in the Zacks Consensus EPS estimate [6] - The Medical - Biomedical and Genetics industry, which includes Moderna, has a Zacks Industry Rank of 97, placing it in the top 40% of over 250 industries [7]